Anlotinib, a broad-spectrum anti-tumor drug designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret, has shown manageable toxicity, long circulation, and anti-tumor potential in patients with advanced refractory solid tumors in phase I clinical trials [39]. This evidence concerns the gene KIT and neoplasm.